Brokerages Set Haleon plc (NYSE:HLN) Price Target at $10.95

Haleon plc (NYSE:HLN - Get Free Report) has been given an average rating of "Buy" by the six brokerages that are covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a hold rating, four have given a buy rating and one has assigned a strong buy rating to the company. The average twelve-month target price among brokerages that have covered the stock in the last year is $10.95.

A number of brokerages have recently commented on HLN. The Goldman Sachs Group lowered Haleon from a "buy" rating to a "neutral" rating in a report on Tuesday, August 6th. Morgan Stanley raised their price target on shares of Haleon from $9.90 to $10.95 and gave the stock an "overweight" rating in a research report on Friday, September 20th. UBS Group raised Haleon to a "strong-buy" rating in a report on Tuesday. Finally, Berenberg Bank assumed coverage on Haleon in a research report on Tuesday, August 6th. They set a "buy" rating on the stock.

Hedge Funds Weigh In On Haleon

Hedge funds have recently modified their holdings of the stock. Janney Montgomery Scott LLC raised its stake in Haleon by 182.3% during the first quarter. Janney Montgomery Scott LLC now owns 438,833 shares of the company's stock worth $3,726,000 after acquiring an additional 283,410 shares in the last quarter. Capstone Investment Advisors LLC bought a new position in shares of Haleon in the first quarter valued at approximately $1,969,000. Wellington Management Group LLP boosted its holdings in shares of Haleon by 164.6% in the 4th quarter. Wellington Management Group LLP now owns 13,542,346 shares of the company's stock worth $111,454,000 after acquiring an additional 8,423,475 shares in the last quarter. Douglas Lane & Associates LLC grew its position in Haleon by 2.1% during the 1st quarter. Douglas Lane & Associates LLC now owns 8,401,876 shares of the company's stock worth $71,332,000 after acquiring an additional 175,082 shares during the last quarter. Finally, Procyon Advisors LLC increased its holdings in Haleon by 559.9% during the 1st quarter. Procyon Advisors LLC now owns 131,665 shares of the company's stock valued at $1,118,000 after purchasing an additional 111,713 shares in the last quarter. 6.67% of the stock is owned by institutional investors and hedge funds.

Haleon Stock Performance

NYSE:HLN traded down $0.14 during midday trading on Thursday, reaching $10.40. The stock had a trading volume of 4,605,359 shares, compared to its average volume of 5,066,372. The stock has a market capitalization of $47.49 billion, a P/E ratio of 34.47, a PEG ratio of 3.12 and a beta of 0.26. Haleon has a 1-year low of $7.70 and a 1-year high of $10.80. The company has a debt-to-equity ratio of 0.44, a current ratio of 0.84 and a quick ratio of 0.58. The firm's fifty day simple moving average is $10.04 and its 200-day simple moving average is $8.99.

Haleon (NYSE:HLN - Get Free Report) last issued its quarterly earnings results on Thursday, August 1st. The company reported $0.08 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.09 by ($0.01). Haleon had a net margin of 9.71% and a return on equity of 13.15%. The business had revenue of $3.50 billion during the quarter, compared to analyst estimates of $3.55 billion. During the same period in the prior year, the business posted $0.08 earnings per share. On average, equities research analysts forecast that Haleon will post 0.47 EPS for the current fiscal year.

Haleon Cuts Dividend

The business also recently disclosed a semi-annual dividend, which was paid on Thursday, September 19th. Shareholders of record on Friday, August 16th were issued a dividend of $0.0514 per share. This represents a yield of 1.6%. The ex-dividend date of this dividend was Friday, August 16th. Haleon's payout ratio is 33.33%.

About Haleon

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.